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Objectives. This study was specifically designed to evaluate
whether noninfarcted hypertrophic myocardium in patients with
end-stage heart failure after myocardial infarction (MI) is asso-
ciated with an increase in interstitial fibrous tissue.
Background. Postinfarction remodeling consists of complex
alterations that involve both infarcted and noninfarcted myocar-
dium. The question arises whether ventricular dysfunction is due
to physical events, such as inadequate myocardial hypertrophy to
compensate for increased tangential wall stress, or is caused by
the development of progressive interstitial fibrosis in noninfarcted
myocardium.
Methods. Fifteen hearts were obtained as cardiac explants (n 5
13) or at autopsy (n 5 2) from patients with end-stage coronary
artery disease. Sixteen normal hearts served as reference hearts.
Samples were taken from the left ventricular (LV) wall that
contained the infarcted area, the border area and noninfarcted
myocardium remote from scar areas. Collagen was quantified
biochemically and microdensitophotometrically. Collagen type I
and III ratios were analyzed by using the cyanogen bromide
method and immunohistochemical staining, followed by micro-
densitophotometric quantification.
Results. In noninfarcted myocardium remote from the scar
areas, total collagen levels and collagen type I/III ratios did not
differ statistically from those in reference hearts. These observa-
tions contrasted with high total collagen content and high colla-
gen type I/III ratios in scar and border areas.
Conclusions. Remodeling of LV myocardium after MI in pa-
tients with end-stage heart failure is not necessarily associated
with interstitial fibrosis in noninfarcted hypertrophic myocar-
dium remote from scar areas. This finding raises questions
regarding therapeutic interventions designed to prevent or retard
the development of interstitial fibrosis.
(J Am Coll Cardiol 1997;30:76–82)
©1997 by the American College of Cardiology
Myocardial infarction (MI) impairs ventricular pump function
because of loss of myocardial cells. In the immediate postin-
farction state, systolic dysfunction leads to an increase in
ventricular volume, both end-systolic and end-diastolic, in
association with chamber dilation, which basically acts as a
compensatory mechanism to increase ventricular stroke vol-
ume (1). At the structural level, volume load hypertrophy of
the remaining viable and noninfarcted myocardium compen-
sates for the loss of muscle and helps to restore ventricular
function (2). In some patients, however, the infarct may show
thinning and disproportionate lengthening, causing regional
ventricular dilation, a phenomenon known as “infarct expan-
sion” (3,4). This occurs early, usually within hours after the
onset of infarction, only in patients with transmural infarction
and predominantly in those with a large anterior infarction
(5,6). Adaptive hypertrophy of the noninfarcted myocardium
will readily occur, but it appears inadequate to fully compen-
sate for the increased volume load and related elevation in
diastolic wall stress, thus causing structural chamber dilation
(7). The complex alterations in ventricular architecture that
take place, which involve both infarcted and noninfarcted
myocardium, are collectively named “ventricular remodeling.”
Clinical studies (5,6,8–10) have shown unequivocally that
early infarct expansion and ventricular chamber dilation are
indicative for progressive ventricular enlargement and even-
tual heart failure. The question arises why progressive deteri-
oration occurs under these circumstances. Some investigators
(1,11) have suggested that chamber dilation with an increase in
diastolic and systolic wall stresses would stimulate further
ventricular enlargement and, hence, a vicious cycle leading to
heart failure. Other investigators have emphasized that an
increase in interstitial collagen in the noninfarcted hypertro-
phic myocardium plays a role. This concept is based largely on
experimental studies in animals (see Weber et al. [12] for
review) and a few studies in humans (13–16). According to
these investigators, interstitial myocardial fibrosis develops
throughout the noninfarcted myocardium, thus producing pro-
gressive myocardial stiffening with further impairment of sys-
tolic and diastolic ventricular function. At present, the concept
of interstitial fibrosis as an intrinsic component of remodeling
of noninfarcted myocardium seems widely accepted (12,16,17).
Indeed, current experimental studies (12,17–19) are directed
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toward the regulation of ventricular loading conditions to
prevent development of interstitial fibrosis.
In view of the clinical importance of the concept of remod-
eling, in this study we quantified not only total collagen
content, but also the ratio between types I and III collagen,
with particular emphasis on the noninfarcted myocardium, in
explanted and autopsy hearts of patients with chronic heart
failure due to ischemic heart disease.
Methods
Heart specimens. The hearts studied were obtained from
15 patients (3 women, 12 men) with end-stage MI. Severe,
long-standing (.12 months) and progressive heart failure had
developed in all patients. All were in New York Heart Asso-
ciation functional class IV; all were treated with a similar
regimen of diuretic drugs, inotropic drugs and angiotensin-
converting enzyme (ACE) inhibitors; and all were selected for
heart transplantation. Blood pressure had been elevated in
some patients, but none had been treated specifically for
hypertension. The hearts were sampled as cardiac explants
(n 5 13) or were obtained at autopsy (n 5 2). The autopsy
hearts became available within 10 h after death. The patients
ranged in age from 33 to 70 years (mean 51). Hearts from 16
age-matched adult patients (8 women and 8 men, mean age 52
years) who died of noncardiovascular-related disease served as
a reference group.
The cardiac explants were obtained from three centers: the
Academic Hospital in Utrecht, The Netherlands (n 5 8);
Harefield Hospital, Middlesex, England, United Kingdom
(n 5 3) and St. George’s Hospital, London, England, United
Kingdom (n 5 2). The five cardiac explants from the United
Kingdom were processed according to protocol as follows. A
cross-section was made of the left ventricle (LV), perpendic-
ular to the ventricular long axis, at the level of the papillary
muscles; in the unfixed state a transmural block from the left
lateral wall was snap-frozen in isopentane cooled in liquid
nitrogen. An adjacent block was fixed in 4% buffered formalin.
The eight cardiac explants from The Netherlands were
available intact. Examination of the coronary arteries revealed
extensive three-vessel obstructive atherosclerotic disease in
each. The LV myocardium, in particular, showed extensive
replacement of viable myocardium by scar tissue. The latter
presented in part as regional transmural and often bandlike
fibrous scars and in part as patchy areas of replacement
fibrosis. Each heart showed an estimated infarct size of ;40%
to 60% of the initial LV myocardium. The hearts were further
processed according to protocol as follows. A cross section of
the heart, similar to that obtained in the hearts from the
United Kingdom, was taken (see above); a transmural block
from the left lateral wall of the left ventricle was snap-frozen;
the heart was then fixed in 4% buffered formalin; subsequent
blocks were taken from the fixed heart to include the scar area,
the immediate border area and noninfarcted myocardium
remote from the scar (see example in Fig. 1). The two autopsy
hearts of patients with MI were similarly processed.
Collagen. Collagen was quantified by using a biochemical
and a histochemical technique. The biochemical method (hy-
droxyproline analysis) allows quantification of total collagen,
which is expressed in mg collagen/mg tissue. The histochemical
method uses Sirius red to stain all fibrillar collagens, which are
quantified spectrophotometrically. Hence, the absolute figures
are not the same, but comparisons between the two techniques
are valid with respect to trends.
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
LV 5 left ventricle; left ventricular
MI 5 myocardial infarction
Figure 1. Cross sections perpendicular to the left ventricular long axis
of a heart with end-stage ischemic heart disease. A, Gross specimen.
The heart is dilated and contains a large transmural infarct scar in the
anterior wall, extending into the upper part of the ventricular septum
and far laterally almost to the base of the posteromedial papillary
muscle. The noninfarcted hypertrophic myocardium reveals a few
patches of scar tissue (compare with B). The sites where blocks have
been taken are indicated: 1 5 scarred area; 2 5 border area; 3 5
noninfarcted myocardium as it appears grossly. B, Histologic section
corresponding to the cross section shown in A, stained with Sirius red.
Small scars within otherwise noninfarcted myocardium are distinct and
more readily identified than in the gross specimen.
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Hydroxyproline analysis. Eight heart specimens with MI and
16 reference hearts were used. Formalin-fixed blocks from the
scar area, the border area and the noninfarcted myocardi-
um—as indicated previously—were frozen in liquid nitrogen.
Sections were cut at 20-mm thickness and collected in a cold
Eppendorf test tube, and the exact wet weight of the tissue was
determined. Total collagen concentration was determined by
measuring the hydroxyproline levels according to the method
of Stegemann and Stalder (20), and the data were expressed as
mg collagen/mg wet weight of tissue (20).
Sirius red staining. Sirius red specifically stains all types of
fibrillar collagen (21). The same eight cardiac explants with MI
and 10 reference hearts were used. Tissue samples were taken
from the same three sites selected for the hydroxyproline
analysis. The advantage of the Sirius red staining method is
that the sections of noninfarcted myocardium, remote from the
scar, could be screened microscopically for the presence of
small areas of replacement fibrosis, unnoticable to the naked
eye, before microspectrophotometry (Fig. 1). In this way we
felt confident that the total amount of fibrillar collagen was
quantified in truly noninfarcted myocardium.
All samples were embedded in paraffin, sectioned at 5-mm
thickness and stained with Sirius red (0.1% Sirius red F3BA
dissolved in saturated picric acid, pH 2.0).
The total amount of fibrillar collagen and that of all
proteins was quantified spectrophotometrically by using a
Vickers M85A scanning and integrating microdensitometer
(22,23). The maximal absorption for Sirius red is at a wave-
length of 557 nm, and that for total bound picric acid is at
434 nm. From each section 20 nonoverlapping areas were
measured at a wavelength of 557 nm and 10 at a wavelength of
434 nm. For each section the mean of the measurements at
557 nm was calculated and divided by the mean of the 10
readings at 434 nm and multiplied by 100 (22,23). The inte-
grated absorbance readings were converted into arbitrary units
of the mean integrated absorbance values.
Types I and III collagen. For determination of the type
I/type III collagen ratio, only frozen tissue samples could be
used (blocks from the LV lateral wall, snap-frozen in isopen-
tane cooled in liquid nitrogen). Two techniques were em-
ployed: a biochemical technique (cyanogen bromide analysis),
using spectrophotometric quantification, and an immunohisto-
chemical method that allowed identification of the tissue
components before microdensitophotometric quantification.
Cyanogen bromide analysis. Eight heart specimens with MI
and 10 reference hearts were used. Cryostat sections were cut
at 20-mm thickness, collected in an Eppendorf test tube and
treated with 2% sodium dodecyl sulfate in 0.1 mol/liter Tris
HCl buffer (pH 7.2) for 24 h at room temperature. The
homogenates were centrifuged at 4,000 rpm for 10 min. The
pellet was resuspended in 250 ml 70% vol/vol formic acid and
5 ml cyanogen bromide crystals (stock solution 100 mg/ml). The
digestion time was 24 h under mixing conditions at 30°C. The
residue was vacuum dried. The resulting peptides were sepa-
rated by sodium dodecyl sulfate polyacrylamide gel electro-
phoresis. For reference purposes, types I and III collagen
standards were prepared from human leiomyoma tissue, as
described by ChandraRajan (24). When gel electrophoresis
was completed, the gel was removed and stained for 30 min by
gentle shaking in an aqueous solution containing 0.125%
Coomassie blue R250, 50% methanol and 10% acetic acid. The
gel was destained by continuous shaking using a solution of
10% acetic acid and 50% methanol in distilled water. Gels
were scanned by using a LKB laser spectrophotometer. The
areas beneath the peaks were calculated by computerized
integration. The al(III)CB3.6.8 peptide was used to quantify
the percentage of type III collagen (25), based on the following
calculation:
% Type III 5
Area al~III!CB3.6.8 3 100
% Area type III standard 3 Total area all peaks
.
The results were expressed as the type I/type III collagen ratio.
Immunohistochemical analysis. Fifteen heart specimens
with MI and 16 reference hearts were used. Cryostat sections
were cut at 6-mm thickness mounted on organosilan-coated
glass slides, dried overnight at room temperature and fixed in
cold acetone for 10 min at 4°C.
Types I and III collagen were immunostained with mouse
anti-type I collagen and mouse anti-type III collagen (clone
I-8H5, immunoglobulin G2a and clone III-53, immunoglobulin
G1, respectively; both gifts of Dr. K. Iwata, Fuji Chemical
Industries Ltd., Toyama, Japan). The method applied was a
two-step indirect immunoalkaline phosphatase technique. The
end product was visualized with fast red, and types I and III
collagen were quantified with a microdensitophotometer at a
wavelength of 500 nm (26). Leiomyoma tissue, known to have
a type I/type III collagen ratio of ;1 (27), was used to establish
the appropriate dilutions of the anticollagen antibodies to
achieve identical optical densities, and it served as a reference
to correct the ratio obtained for the collagens. The results were
expressed as the type I/type III collagen ratio.
Statistical methods. The results obtained for scar areas,
border zones and noninfarcted myocardium, remote from the
scars, were analyzed by Student t test. The statistical signifi-
cance of the calculated ratios of collagen types I and III was
analyzed by both Student t test and Mann-Whitney test.
Results
Collagen. Hydroxyproline analysis (Table 1). The 16 adult
reference hearts had a mean value (6 SD) of collagen of 5.8
(6 1.5) mg/mg wet weight of tissue in the LV. Collagen values
showed no relation with patient age or gender. Each of the
eight hearts with MI used in this analysis showed a high total
collagen content in the scar area; in seven of the eight hearts,
values were lower in the border zone. Values in noninfarcted
myocardium remote from the scar were much lower in all eight
hearts. The mean value of the total collagen amount in
noninfarcted myocardium did not differ statistically from that
of reference hearts.
Sirius red staining (Table 2). Microscopic foci of replace-
ment fibrosis were present in all sections, all of which were
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sampled from the same sites selected for the hydroxyproline
analysis. As stated, such foci were excluded from spectropho-
tometric quantification. The total fibrillar collagen amount is
shown in Table 2. The amount of fibrillar collagen related to
total protein is highest in scar areas and declines markedly in
the border areas and in noninfarcted myocardium. The total
fibrillar collagen amount in noninfarcted myocardium is simi-
lar to that in reference hearts.
Types I and III collagen. Cyanogen bromide analysis. Table
3 shows the calculated percentages of type III collagen and the
type I/type III collagen ratio for reference hearts and the LV
lateral wall of hearts with MI. Hearts with MI showed a mean
(6 SD) type I/type III collagen ratio of 1.06 6 0.38; in
reference hearts this value was 0.60 6 0.14 (p , 0.05 by both
Student t test and Mann-Whitney test). The wide range of
mean values for type I/type III collagen ratio in hearts with MI
relates to the fact that some blocks contained mostly scar and
border areas, whereas others contained substantial areas of
noninfarcted myocardium. The cyanogen bromide method
does not allow identification of these differences before anal-
ysis. However, we know that these differences were present
because they became apparent when the same blocks were
used for immunostaining for collagen types I and III (see
Immunohistochemical analysis; Fig. 2).
Immunohistochemical analysis (Table 4). The mean cor-
rected type I/type III collagen ratio was 0.54 6 0.11 in
reference hearts versus 0.83 6 0.25 in hearts with MI (p , 0.05
by both Student t test and Mann-Whitney test).
Of the 15 blocks obtained from the LV lateral wall, 11
showed scar tissue intermingled with viable myocardial cells
throughout the microscopic sections. In only four blocks a
distinct difference could be seen between noninfarcted myo-
cardium and scar tissue within the same microscopic section.
These four cases allowed us to distinguish between measure-
ments made at sites of scar tissue and those obtained at
noninfarcted areas.
Quantification of the type I/type III collagen ratio in these
four sections with distinct noninfarcted myocardium, without
microscopic scars, showed a corrected ratio of 0.44, 0.77, 0.66
Table 1. Total Collagen, Quantified by Hydroxyproline Analysis, in










48.90 33.80 7.10 5.00
81.20 87.20 10.70 6.80
64.00 30.00 6.80 3.90
26.70 17.70 10.50 6.50
29.40 18.80 8.60 4.60
41.40 26.70 5.30 5.10
45.70 10.70 4.00 5.10












Data are presented as mg/mg tissue wet weight. MI 5 myocardial infarction.
Table 2. Total Fibrillar Collagen, Measured With Sirius Red
Staining and Microdensitophotometry, in Eight Hearts With










0.21 0.09 0.03 0.05
0.24 0.12 0.06 0.05
0.20 0.09 0.05 0.05
0.23 0.09 0.04 0.04
0.23 0.09 0.06 0.06
0.21 0.11 0.05 0.07
0.19 0.100 0.07 0.06




p , 0.05 p 5 NS
Data are expressed as arbitrary units of the mean integrated absorbance
values. The eight postinfarction hearts are the same as those in Table 1. MI 5
myocardial infarction.
Table 3. Percent of Collagen Type III and Ratio of Type I to Type
III Collagen, Quantified by Cyanogen Bromide Analysis, in 8 Hearts
With Myocardial Infarction and 10 Reference Hearts









64.20 0.56 58.00 0.72
41.80 1.39 61.10 0.64
62.20 0.61 60.30 0.66
54.90 0.82 52.90 0.89
47.00 1.13 64.20 0.56
44.10 1.27 67.80 0.47
48.50 1.06 74.20 0.35




*By both Student t test and Mann-Whitney test. MI 5 myocardial infarction.
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and 0.45, respectively. Thus, the mean corrected ratio of these
four sections (0.58 6 0.16) was similar to that seen in reference
hearts. Measurements at sites with scars, but in the same
sections, showed a corrected ratio of 0.71, 0.87, 1.01 and 0.88,
respectively, and hence, a higher type I/type III collagen ratio
(mean 0.87 6 0.12).
Discussion
Two important aspects emerge from this study. First, non-
infarcted hypertrophic myocardium, remote from the site of
myocardial scar tissue, does not show an increase in interstitial
fibrous tissue. In fact, the endomysial collagen network at these
sites presents the same ratio between types I and III collagen
seen in reference hearts. Second, at the site of the scar the ratio
between types I and III collagen is greater than the ratio that
occurs normally in endomysial and perimysial sites.
Remodeling. It is currently in vogue to consider postinfarc-
tion remodeling of LV myocardium in terms of a myocyte and
a nonmyocyte compartment (12,17,28,29). Indeed, functional
integrity of myocardium is highly dependent on structural
characteristics of the extracellular matrix. The collagen net-
work, composed largely of types I and III fibrillar collagen, is
a major constituent for the preservation of myocardial archi-
tecture and chamber geometry. It is of interest in this context
that factors that promote myocyte growth are largely different
from those that contribute to changes in the collagen network.
In the setting of postinfarction myocardial remodeling the
prime stimulus for hypertrophy of noninfarcted myocardium is
volume overload. This type of ventricular hypertrophy is not
associated with an increase in interstitial collagen, in contrast
to pressure overload hypertrophy, which is accompanied by an
increase in collagen and structural and biochemical remodel-
ing of the collagen matrix (28). The fibrogenetic factors
involved are still under investigation, but it appears that
elevated levels in circulating angiotensin II and aldosterone
may play a role, as well as local tissue factors such as
endothelins and bradykinin (30). Once interstitial fibrosis
develops it will increase myocardial stiffness and, therefore,
will have a negative effect on diastolic and systolic ventricular
function. At this stage hypertrophy of myocardium can no
longer be considered a physiologic adaptation, but rather a
pathologic condition that may set the stage for a vicious cycle
leading to overt heart failure. It has been stated (15,16) that
this provides the structural basis for end-stage heart failure
postinfarction cardiac remodeling.
Remodeling and fibrosis. The observations in the present
series of hearts are pertinent to this concept. All patients
included in the study had end-stage MI. The cardiac explants
all showed extensive scarring (see Methods), in accordance
Figure 2. Frozen sections of tissue blocks used to quantify the type
I/type III collagen ratio. Both sections were obtained from the left
ventricular lateral wall. Both blocks were used for biochemical quan-
tification and immunostaining. The sections shown are stained for type
I collagen. A, Marked fibrosis is evident. B, There is a mild increase in
collagen. These differences underlie the wide range of results obtained
with the biochemical technique. Original magnification 335.
Table 4. Type I/Type III Collagen Ratio Quantified
Spectrophotometrically in 15 Hearts With Myocardial Infarction and
16 Reference Hearts



















*By both Student t test and Mann-Whitney test. Data are expressed as mean
value of the corrected type I/type III collagen ratio. MI 5 myocardial infarction.
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with the clinical course, and all showed distinct global LV
chamber dilation with extensive hypertrophy of noninfarcted
myocardium (see Fig. 1). In other words, in all instances the
condition fit the description of remodeling. However, none of
these hearts had an increase in interstitial fibrous tissue in
noninfarcted myocardium. The total collagen content, mea-
sured biochemically and quantified by using microdensitopho-
tometry, was not greater than that in reference hearts and the
ratio between types I and III collagen was also normal.
At the site of the scar, however, the ratio between both
collagen types had shifted, with an increase in type I over type
III collagen. This observation is in keeping with wound healing
processes in general, since the usual scar contains a similar
increase in type I over type III collagen (31). In human hearts,
this phenomenon may have adverse effects. Type I collagen is
found principally in thick collagen fibers, such as those in
tendons, and is generally associated with tensile strength. Type
III collagen, in contrast, is found in thin fibers and relates to
elasticity. Therefore, the change in type I/type III collagen
ratio in myocardial scar tissue may cause undue stiffness with a
negative net effect on myocardial performance.
Myocardium in the immediate border zone of the scar,
made up of connective tissue extensions of the scar intermin-
gling with viable myocardium, showed an increase in total
collagen and also an increase in type I over type III collagen.
When the levels were quantified, they were below those
obtained within the scar but significantly higher than those
found at sites of noninfarcted myocardium remote from the
scar. We encountered one exception (Case 2, Table 1) in which
hydroxyproline analysis revealed almost the same high levels of
collagen in the scar as in the immediate border zone. Because
the technique does not allow for visual identification of the
tissue components, the only explanation that we can offer is
that both sites represented excessive replacement fibrosis. We
feel strengthened in this view, because the adjacent tissue
block, used for Sirius red staining and microdensitophotomet-
ric quantification (Case 2, Table 2), revealed a decrease in
collagens in the border area as in other cases.
Comparison with previous studies. The present observa-
tions are at variance with recent reports (13–16) claiming that
postinfarction remodeling is associated with an increase in
interstitial fibrous tissue in noninfarcted myocardium. These
reports differ among themselves and to some extent are even
inconsistent. For instance, Bishop and coworkers (13) found
enhanced deposition of predominantly type I collagen,
whereas Mukherjee and Sen (14) found increased deposition
of type III collagen. The first group of investigators stated
specifically that they avoided regions that were macroscopically
replaced by scar tissue, whereas the second group stated that
they removed tissue from the LV apex, avoiding the infarcted
area of the myocardium. Both groups studied collagen by using
biochemical analysis only, without microscopic verification of
the tissue architecture. Apart from the conflicting results, the
question arises whether other factors may have played a role in
the data obtained. Because both groups took full thickness
blocks of myocardium, one may consider the option that
endocardial thickening, likely to be present in a heart with
chronic dilation, may have affected the outcome.
Volders and associates (15) stated that “myocardial tissue
from the interventricular septum was routinely sampled during
autopsies.” They studied hearts with a transmural infarct in the
anterior, posterior or lateral part of the LV, excluding hearts
with an interventricular septal infarct. They quantified collagen
by using the Sirius red staining technique, as in our study.
However, they found a significantly greater amount of collagen
in the septum of patients with infarction than in the control
group without infarction. It may be relevant to this point that
patients with end-stage heart failure after MI usually have a
large infarct, and streaks of scar tissue that often extend into
adjacent noninfarcted myocardium, far beyond the scar readily
distinct to the naked eye (see Fig. 1). Therefore, it may well be
that the “routinely” sampled site in the interventricular septum
contained extensions from the neighboring scar or isolated
small areas of replacement fibrosis. This option is strengthened
by their Figure 1A (15), which clearly shows replacement
fibrosis. We also frequently encountered microscopic patches
of replacement fibrosis (microscopic scars) in the apparent
noninfarcted myocardium, but we excluded such areas from
our measurement of the interstitial compartment of nonin-
farcted myocardium.
Finally, Beltrami and associates (16) produced an extensive
study on the ventricular characteristics in cardiac explants of
patients with end-stage coronary artery disease. They reported
diffuse interstitial fibrosis of myocardium at sites remote from
the infarcted region (see their Fig. 3B). Their observations
were based on six randomly chosen embedded tissue blocks,
stained with a trichrome stain, and the volume fraction of the
nonmyocyte compartment was estimated by using a point
counting system. In other words, they measured the total
extracellular matrix and, given their staining technique, did not
specifically measure collagens. Thus, the increase found could
be anything affecting the nonmyocyte compartment, such as an
increase in water content. Moreover, they did not specifically
select blocks from noninfarcted areas. In fact, they stated that
the randomly selected blocks did contain extensive scarring, as
well as patchy areas of replacement fibrosis, and it remains
unclear whether any of these blocks contained no scar tissue at
all. We wonder, therefore, whether the blocks are truly repre-
sentative for noninfarcted myocardium.
Study limitations. All patients enrolled in our study had
been treated with ACE inhibitors, known to decrease fibro-
genesis (14). One could argue, therefore, that the absence of
interstitial fibrosis in noninfarcted myocardium, remote from
the scars, was due to this medication. However, each patient
had extensive myocardial scar formation, with compensatory
hypertrophy of viable myocardium and global LV dilation, and
each had progressive LV dysfunction with overt heart failure;
in other words each met the criteria for ventricular remodeling,
generally considered to be associated with an increase in
interstitial fibrosis. Nevertheless, in this study, interstitial fibro-
sis in noninfarcted myocardium was not greater than that in
reference hearts, despite the fact that the gross anatomic and
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clinical findings all fitted with progressive postinfarction LV
dysfunction. Indeed, according to current concepts, the ab-
sence of an increase in interstitial fibrosis should have led to a
stable rather than to a deteriorating clinical condition. We
wonder, therefore, whether the beneficial effects of ACE
inhibitors are truly due to their inhibiting effects on fibrogen-
esis.
Conclusions. We feel confident that the noninfarcted myo-
cardium of the hearts with MI that we studied contained no
increase of collagens in the nonmyocyte compartment. We
therefore believe that the basic structural processes of postin-
farction remodeling of LV myocardium are replacement fibro-
sis of necrotic myocardium, leading to scar tissue, and myocar-
dial hypertrophy of noninfarcted myocardium without
interstitial fibrosis. The mechanisms that cause progressive LV
dysfunction in some patients may well relate to physical effects
(1,11). In patients in whom remodeling is associated with an
increase in interstitial fibrosis of the noninfarcted myocardium,
other processes known to increase interstitial fibrous tissue
may be at work. An increase in pressure load, added to an
increase in volume load, could be one of those factors (18).
These considerations are relevant clinically. Because post-
infarction remodeling with progressive LV deterioration is not
necessarily due to progressive interstitial fibrosis, it may be
necessary to reconsider therapeutic attempts to prevent the
fibrosis or reduce its severity.
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